Subcutaneous Infliximab (CT-P13 SC) as Maintenance Therapy for Inflammatory Bowel Disease: Two Randomized Phase 3 Trials (LIBERTY).

Subcutaneous Infliximab (CT-P13 SC) as Maintenance Therapy for Inflammatory Bowel Disease: Two Randomized Phase 3 Trials (LIBERTY). Gastroenterology. 2024 Oct; 167(5):919-933.

View in: PubMed

subject areas

Adult
Antibodies, Monoclonal
Biosimilar Pharmaceuticals
Colitis, Ulcerative
Crohn Disease
Double-Blind Method
Female
Gastrointestinal Agents
Humans
Infliximab
Injections, Subcutaneous
Maintenance Chemotherapy
Male
Middle Aged
Remission Induction
Severity of Illness Index
Time Factors
Treatment Outcome
Young Adult

authors with profiles

Stephen B. Hanauer